TriSalus Life Sciences, Inc. Operating Income Loss

• TriSalus Life Sciences, Inc. showed an increase of +25.5% in Operating Income Loss from 2024 to 2025.
• This data is from TriSalus Life Sciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
• XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 5 years of available data (2021 to 2025), TriSalus Life Sciences, Inc.'s Operating Income Loss has declined by 786.2%.
• Historical annual values: Fiscal year 2025: -$26.95 million | Fiscal year 2024: -$36.17 million | Fiscal year 2023: -$54.48 million | Fiscal year 2022: -$36.44 million | Fiscal year 2021: -$3.04 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026